🏛️ Verified NIH Record • Updated 2026-04-24

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04384484)

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: ADC Therapeutics S.A.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Who can join: Review the eligibility criteria below.

Location: University of California San Diego Moores Cancer Center — La Jolla, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (144 Sites)

Showing the first 25 of 144 sites.

  • University of California San Diego Moores Cancer Center — La Jolla, California
  • Redlands Community Hospital — Redlands, California
  • The Oncology Institute of Hope and Innovation — Whittier, California
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
  • UnityPoint Health - Iowa Oncology Research Association (IORA) — Des Moines, Iowa
  • Norton Cancer Institute — Louisville, Kentucky
  • Comprehensive Cancer Centers of Nevada - Henderson — Las Vegas, Nevada
  • Kaiser Permanente Interstate Medical Office Central — Portland, Oregon
  • Hollings Cancer Center — Charleston, South Carolina
  • Virginia Cancer Specialists — Gainesville, Virginia
  • Medical College of Wisconsin Cancer Center Clinical Trials Office — Milwaukee, Wisconsin
  • Clinica Adventista Belgrano — Belgrano, Buenos Aires
  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares S.A. — Santa Fe, Buenos Aires
  • Instituto Médico Especializado Alexander Fleming — Buenos Aires, Distrito Federal
  • Grupo Gamma - Hospital Privado Rosario — Rosario, Santa Fe Province
  • Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan — Bruges,
  • Cliniques Universitaires Saint-Luc — Brussels,
  • Centre Hospitalier Universitaire Universite Catholique de Louvain — Namur,
  • Algemeen Ziekenhuis Delta - Campus Rumbeke — Roeselare,
  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer — Curitiba, Paraná
  • Hospital Moinhos de Vento — Porto Alegre, Rio Grande do Sul
  • Hospital de Clínicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
  • Hospital Mãe de Deus - Centro Integrado de Oncologia — Porto Alegre, Rio Grande do Sul
  • Hospital do Câncer — Rio de Janeiro,
  • Hemomed Instituto de Oncologia e Hematologia — São Paulo,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed Diffuse Large B-Cell Lymphoma

Explore by condition: All Relapsed Diffuse Large B-Cell Lymphoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗